Seneca Growth Capital VCT Plc (the "Company")

16 September 2020

Realisations of Ordinary Share Investments and New Ordinary Share Net Asset Value (“NAV”).

Full Realisation of Ordinary Share Investment in Omega Diagnostics Group plc (“Omega”)

Following the recent rise in Omega’s share price on AIM, the Company has sold the remaining 400,000 Omega shares it retained, realising £296,166, an increase of £132,166 (unaudited) on their carrying value as at 30 June 2020, being the date of the most recently announced NAV per Ordinary Share. The Company has now sold a total of 2,293,868 Omega shares from the Ordinary Share pool since 31 December 2019 fully realising the investment for a total of £987,318 and generating a profit versus original cost of £659,318 (a 3x return on the original investment).

Partial Realisation of Ordinary Share Investment in Scancell Holdings Plc (“Scancell”)

The Directors are also pleased to report that the Company has sold 1,049,730 Scancell shares from the Ordinary Share pool, realising £126,619 and generating a profit versus original cost of £63,110 (a 2x return on the original investment) and an increase of £72,033 on their carrying value as at 30 June 2020. The Company’s Ordinary Share pool retains 12,000,000 Scancell shares.

New Ordinary Share Net Asset Value

The Board have reviewed the carrying value of all Ordinary Share pool investments, including Scancell at a bid price of 15p per share as at 14 September 2020, and report that as at 14 September 2020 the unaudited NAV per Ordinary share was 35.8p, an increase of 13.6p per Ordinary share from the unaudited NAV of 22.2p per Ordinary share (the unaudited NAV as at 30 June 2020 net of the dividend of 8p per Ordinary Share that was paid on 28 August 2020). This increase is a result of the profit generated on the sale of Omega and Scancell shares, and the increase in value of the remaining Scancell shares, net of the associated movement in the performance fee accrual.

The information above is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via a Regulatory Information Service this inside information is now considered to be in the public domain.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk